Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination therapy consisting of topical adapalene 0.1% gel and oral doxycycline 100 mg/day, utilized as the conventional therapy comparator in clinical research conducted by the Pontificia Universidad Católica de Chile. Adapalene is a naphthoic acid derivative with retinoid activity that selectively binds to nuclear retinoic acid receptors (RAR-beta and RAR-gamma), leading to the normalization of follicular epithelial cell differentiation and reduction of comedone formation. Doxycycline is a broad-spectrum tetracycline antibiotic that inhibits protein synthesis by binding to the 30S ribosomal subunit of susceptible bacteria, including Cutibacterium acnes, and provides additional anti-inflammatory benefits by inhibiting neutrophil chemotaxis and matrix metalloproteinases. This combination is a standard-of-care approach for moderate inflammatory acne vulgaris.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on adapalene + doxycycline.